NCT02953314View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

Cystic Fibrosis

Interventions

DRUG

TEZ

DRUG

TEZ/IVA

DRUG

IVA

Trial Locations (33)

Unknown

Birmingham

Anchorage

Little Rock

Los Angeles

Palo Alto

Aurora

Wilmington

Orlando

St. Petersburg

Atlanta

Boise

Indianapolis

Boston

Minneapolis

Kansas City

Manchester

Buffalo

New York

Syracuse

Winston-Salem

Cleveland

Pittsburgh

Charleston

Sioux Falls

Austin

Fort Worth

Houston

Norfolk

Seattle

Milwaukee

Vancouver

Toronto

Montreal

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02953314 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) | Biotech Hunter | Biotech Hunter